Bioreductive drugs: from concept to clinic.

@article{McKeown2007BioreductiveDF,
  title={Bioreductive drugs: from concept to clinic.},
  author={Stephanie R. McKeown and Rachel L. Cowen and Kaye J. Williams},
  journal={Clinical oncology (Royal College of Radiologists (Great Britain))},
  year={2007},
  volume={19 6},
  pages={
          427-42
        }
}
One of the key issues for radiobiologists is the importance of hypoxia to the radiotherapy response. This review addresses the reasons for this and primarily focuses on one aspect, the development of bioreductive drugs that are specifically designed to target hypoxic tumour cells. Four classes of compound have been developed since this concept was first proposed: quinones, nitroaromatics, aliphatic and heteroaromatic N-oxides. All share two characteristics: (1) they require hypoxia for… Expand
Gene therapy approaches to enhance bioreductive drug treatment.
TLDR
The metabolic requirements for their activation are considered and the key in vivo studies supporting the future clinical development of hypoxia-targeted gene-directed enzyme prodrug therapy are highlighted. Expand
Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
TLDR
The clinical progress of hypoxia-activated prodrugs as adjuncts to radiation therapy is reviewed and it is concluded that the use of HAPs alongside radiation is vastly underexplored at the clinical level. Expand
Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials.
TLDR
The preclinical validation of 1-bromoacetyl-3,3-dinitroazetidine (ABDNAZ) offers preclinical proof-of-concept for ABDNAZ as a promising new anticancer agent with a favorable toxicity profile, either as a chemotherapeutic agent or a radiosensitizer. Expand
Prodrug Strategies for Targeting Tumour Hypoxia
TLDR
An overview of recent progress towards four classes of hypoxia-activated prodrugs (HAPs) in clinical trial or in advanced preclinical development is provided, namely benzotriazine di-oxides, the dinitrobenzamide mustard (DNBM) PR-104, the phosphoramidate mustard TH-302 and nitrochloromethylbenzindoline (nitroCBI) pro drugs of potent DNA minor groove alkylators. Expand
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.
TLDR
A series of achiral hypoxia-activated prodrugs synthesized on the basis of the DNA cross-linking toxin of the prodrug, ifosfamide, have emerged as a promising antitumor agent that shows excellent in vivo efficacy and is currently being evaluated in the clinic. Expand
ROLES OF BIOTRANSFORMATION IN THE ANTITUMOUR ACTIVITY AND TOXICOLOGY OF THE HYPOXIA-ACTIVATED PRE- PRODRUG PR-104
Hypoxia is a characteristic of tumours and an attractive therapeutic target. PR-104, a hypoxia-activated prodrug in clinical trial, is a phosphate ester which is rapidly converted to the alcoholExpand
Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling
TLDR
A spatially resolved pharmacokinetic/pharmacodynamic (SR-PK/PD) model shows that Class II HAP offer advantages over Class I including higher tumor selectivity and greater freedom to vary prodrug diffusibility and rate of metabolic activation, and suggests that the largest gains could be realized by optimizing effector stability and prodrug activation rates. Expand
Design of anticancer prodrugs for reductive activation
TLDR
This review mainly focuses on the medicinal chemistry aspects of various classes of reductively activated prodrugs including design principles, structure‐activity relationships, and mechanisms of activation and release of active drug molecules. Expand
Tumour endoproteases: the cutting edge of cancer drug delivery?
TLDR
The concept behind development of tumour‐endoprotease activated prodrugs is described and the various studies to date that have demonstrated the huge potential of this approach for improvement of cancer therapy are discussed. Expand
In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts
TLDR
This is the first demonstration that AQ4N will increase the efficacy of chemoradiotherapy in preclinical models; the intratumoral levels of AQ4 found in this study are comparable with tumor AQ4 levels found in a recent phase I clinical study, which suggests that these levels could be potentially therapeutic. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 176 REFERENCES
The Design of Drugs that Target Tumour Hypoxia
The occurrence of hypoxia in solid tumours is increasingly recognized as a limiting factor in the success of both radiotherapy and chemotherapy treatment, but at the same time offers aExpand
AQ4N: a new approach to hypoxia-activated cancer chemotherapy
TLDR
AQ4N is a bioreductive prodrug of a potent, stable, reduction product which binds non-covalently to DNA, facilitating antitumour activity in both hypoxic and proximate oxic tumour cells. Expand
Hypoxia Targeted Gene Therapy to Increase the Efficacy of Tirapazamine as an Adjuvant to Radiotherapy
TLDR
A gene-directed enzyme prodrug therapy approach using adenoviral delivery, which overexpressed human P450R specifically within hypoxic cells in tumors, with the aim of harnessing hypoxia as a trigger for both enzyme expression and drug metabolism. Expand
Bioreductive and gene therapy approaches to hypoxic diseases.
TLDR
The potential of utilising hypoxia to deliver selective gene therapy based upon the transcription factor HIF-1 and the use of unique genetic sequences termed HRE's (hypoxia responsive elements) that specifically control gene expression under hypoxic conditions are discussed. Expand
Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine
TLDR
Investigations with three-drug combination treatments using cisplatin and TPZ with either etoposide or navelbine indicated a substantial therapeutic gain from the addition of TPZ. Expand
Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.
TLDR
In the model, an increase in the therapeutic index was obtained for radiation treatment when either AQ4N or tirapazamine was administered concurrently, and this was in contrast to mitomycin C which had a marked effect on the radiation induced functional deficit. Expand
Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
TLDR
It is demonstrated that TPZ potentiates tumor cell kill by fractionated radiation in three murine tumors and two human tumor xenografts with no potentiation observed in a third Xenograft, with the results suggesting that the sensitivity of individual tumors to TPZ, although not necessarily the response to TPz plus radiation, might be assessed from measurements of DNA damage using the comet assay. Expand
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
TLDR
In combination with chemotherapy it is shown that AQ4N potentiates the activity of cyclophosphamide, cisplatin and thiotepa, and provides indirect evidence that in the combination chemotherapy experiments there is some tumour selectivity in the enhanced action of the drugs. Expand
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
TLDR
The pharmacokinetics of E09 showed its rapid elimination from the central compartment but with wide interpatient variation in the overall disposition of the drug, which suggested a loss of glomerular negative charge consistent with a minimal change glomerulopathy. Expand
Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells.
TLDR
Differences in the uptake and retention of Por are associated with the preferential toxicity of Por to hypoxic cells, and these differences are directly correlated with cytotoxicity under both aerobic and hypoxic conditions. Expand
...
1
2
3
4
5
...